Akebia Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Akebia Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, and proposes a significant increase in authorized common stock.
NASDAQ
Akebia Therapeutics, Inc. will hold its annual meeting virtually on June 10, 2025, with several key proposals for shareholders to vote on.
NASDAQ
Akebia Therapeutics is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance and make other changes.
NASDAQ
Akebia Therapeutics will hold its annual meeting on June 6, 2024, featuring proposals including director elections, stock incentive plan amendments, executive compensation, and auditor ratification.
NASDAQ
DEF 14A: Akebia Therapeutics Seeks Stockholder Approval for Increased Share Issuance Under Incentive Plan
Akebia Therapeutics is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance by 9,800,000.